HROW Harrow Health Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: HROW

Price (delayed)

$33.6

Market cap

$1.26B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.99

Enterprise value

$1.48B

?
Relative Growth: Rel. Growth: 42
Relative Strength: Rel. Strength: 18
Relative Valuation: Rel. Valuation: 13
Relative Profitability: Rel. Profitability: 25

Harrow, Inc. is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve ...

Highlights
HROW's revenue is up by 21% year-on-year and by 2.6% since the previous quarter
HROW's gross profit is up by 19% YoY
The EPS has dropped by 154% since the previous quarter
Harrow Health's net income has plunged by 149% from the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: https://www.harrow.com
Peers: OPK ORGO

Key stats

What are the main financial stats of HROW

HROW stock price

How has the Harrow Health stock price performed over time
Intraday
-2.47%
1 week
-1.78%
1 month
-17.95%
1 year
-31.22%
YTD
-31.43%
QTD
-20.89%

Financial performance

How have Harrow Health's revenue and profit performed over time
Revenue
$275.59M
Gross profit
$201.96M
Operating income
-$2.75M
Net income
-$37.23M
Gross margin
73.3%
Net margin
-13.5%
Harrow Health's net margin has plunged by 200% YoY and by 141% from the previous quarter
Harrow Health's net income has plunged by 149% from the previous quarter
Harrow Health's operating income has plunged by 119% YoY and by 114% from the previous quarter
HROW's operating margin has dropped by 116% year-on-year and by 114% since the previous quarter

Price vs fundamentals

How does HROW's price correlate with its fundamentals

Growth

What is Harrow Health's growth rate over time

Valuation

What is Harrow Health stock price valuation
P/E
N/A
P/B
82.4
P/S
4.55
EV/EBIT
N/A
EV/EBITDA
129.75
EV/Sales
5.36
The EPS has dropped by 154% since the previous quarter
The stock's price to book (P/B) is 121% more than its 5-year quarterly average of 38.2 and 52% more than its last 4 quarters average of 55.6
Harrow Health's equity has plunged by 69% YoY and by 47% from the previous quarter
HROW's P/S is 23% below its last 4 quarters average of 6.1 and 4.7% below its 5-year quarterly average of 4.9
HROW's revenue is up by 21% year-on-year and by 2.6% since the previous quarter

Efficiency

How efficient is Harrow Health business performance
The return on sales has dropped by 184% since the previous quarter and by 161% year-on-year
The ROIC has plunged by 171% from the previous quarter and by 142% YoY
The return on assets has dropped by 138% since the previous quarter

Dividends

What is HROW's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HROW.

Financial health

How did Harrow Health financials performed over time
The total assets is 3.7% greater than the total liabilities
HROW's total liabilities is up by 36% year-on-year and by 2.8% since the previous quarter
The total assets is up by 21% year-on-year
The debt to equity has soared by 89% from the previous quarter
Harrow Health's equity has plunged by 69% YoY and by 47% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.